Bispecific antibody News and Research

RSS
BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Amgen seeks FDA approval for leukemia drug blinatumomab

Amgen seeks FDA approval for leukemia drug blinatumomab

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

Covagen, TRL expand research collaboration to generate bispecific FynomAb

Covagen, TRL expand research collaboration to generate bispecific FynomAb

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

AAPS recognizes top scientists in pharmaceutical sciences

AAPS recognizes top scientists in pharmaceutical sciences

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

Amgen enters definitive merger agreement to acquire Micromet

Amgen enters definitive merger agreement to acquire Micromet

X-BODY, TRL enter collaboration to identify therapeutic target epitopes

X-BODY, TRL enter collaboration to identify therapeutic target epitopes

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

NovImmune obtains additional financing of CHF 20 million

NovImmune obtains additional financing of CHF 20 million

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics product candidates, technologies receive recognition from QTDP program

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer

Karmanos Cancer Institute awarded $3M NIH grant to study triple-negative breast cancer